生物测定
可交付成果
效力
主题
药物发现
治疗方式
药理学
模式
生物技术
生化工程
计算生物学
质量(理念)
药物开发
生物
计算机科学
医学
制药工业
医学物理学
组分(热力学)
管理科学
主题专家
风险分析(工程)
控制(管理)
标识
DOI:10.1021/acs.molpharmaceut.6c01004
摘要
Bioassay subject matter experts (SMEs) play an increasingly important role in chemistry, manufacturing, and controls (CM&C) organizations as biologic therapeutics become more complex. This review describes how bioassay SMEs support potency method development and CM&C deliverables from early discovery through commercialization. As therapeutic modalities progress, bioassay control strategies have become more sophisticated, evolving from using simple binding assays to multi-attribute, orthogonal testing approaches. The review summarizes the SME's expanding contributions to assay design, optimization, method transfer, phase-appropriate qualification and validation, lot release, stability testing, comparability, and regulatory submissions. A case study on ADC potency assay cell-line selection illustrates how biochemical and biological factors affect assay specificity and impurity discrimination. The review also addresses key scientific, technical, and cross-functional challenges, including assay variability and the need for effective leadership across analytical, regulatory, and quality functions. As biologic modalities continue to diversify, interdisciplinary bioassay SME training will be critical to support regulatory-compliant potency strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI